Beta
Trial Radar KI
Die klinische Studie NCT06904027 für Harnstoffzyklusstörungen ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht

A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders 40 Multizentrisch Pädiatrisch Seltene Krankheit

Offene Rekrutierung
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06904027 ist eine beobachtungsstudie zur Untersuchung von Harnstoffzyklusstörungen und hat den Status offene rekrutierung. Die Studie startete am 9. Dezember 2025 und soll 40 Teilnehmer aufnehmen. Durchgeführt von Tongji Hospital ist der Abschluss für 1. Juli 2031 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 15. Januar 2026 aktualisiert.
Kurzbeschreibung
Urea cycle disorders (UCD) are rare diseases in China, would lead to high mortality and disability, which require long-term management due to the recurrent symptoms. This multi-center, prospective, single-arm study was designed to assess the efficacy and safety of Glycerol Phenylbutyrate for Chinese pediatric patients with UCD, to provide the additional references and treatment options for Chinese UCD patients, and e...Mehr anzeigen
Ausführliche Beschreibung
The duration of treatment with GPB in this study was 5 years. Forty participants aged 0-18 years with a diagnosis of UCD, including carbamoyl phosphate synthetase I deficiency, ornithine carbamoyltransferase deficiency, citrullinemia type I, argininosuccinic aciduria, argininemia, or hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, and who plan to use and have not used glycerol phenylbutyrate in the...Mehr anzeigen
Offizieller Titel

A Single-arm, Prospective, Multi-center Post-market Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders

Erkrankungen
Harnstoffzyklusstörungen
Weitere Studien-IDs
  • WH002A401
NCT-Nummer
Studienbeginn (tatsächlich)
2025-12-09
Zuletzt aktualisiert
2026-01-15
Studienende (vorauss.)
2031-07
Geplante Rekrutierung
40
Studientyp
Beobachtungsstudie
Status
Offene Rekrutierung
Stichwörter
Chinese
Pediatric patients
Urea cycle disorders
Glycerol phenylbutyrate
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Glycerol phenylbutyrate cohort
Glycerol Phenylbutyrate was used.
Glycerol phenylbutyrate Oral Liquid
Administration and dosage: The recommended total daily dose of glycerol phenylbutyrate is calculated based on the patient's body surface area, ranging from 4.5 mL/m2/d to 11.2 mL/m2/d: 1. Recommended initial dose in phenylbutyrate-naïve patients * Patients with body surface area (BSA) \< 1.3 m2: 8.5 mL/m2/day * Patients with body surface area (BSA) ≥ 1.3 m2: 7 mL/m2/day 2. Initial dose for patients switching ...Mehr anzeigen
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Mean blood ammonia levels at month 3 after enrollment.
The average of blood ammonia levels at months 3 after enrollment.
months 3
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Mean blood ammonia levels
The average of blood ammonia levels at period of baseline, month 1, month 6, and every 6 months thereafter (1-5 years)
Baseline, Month 1, Month 6, and every 6 months thereafter (1-5 years)
Maximum blood ammonia levels
The maximum blood ammonia levels at period of baseline, month 1, month 3, month 6, and every 6 months thereafter (1-5 years)
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Frequency of hyperammonaemic crisis
The frequency of hyperammonaemic crisis at period of baseline, month 1, month 3, month 6, and every 6 months thereafter (1-5 years)
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Height
The change of height to the baseline in children aged 0-18 years old, and the proportion of weight in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old (WS/T 423-2022) and standard for height level classification among children and adolescents aged 7\~18 years (WS/T 612-2018)issued by the National Health Commission of the People's Republic of China.
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years).
Weight
The change of weight to the baseline in children aged 0-7 years old, and the proportion of weight in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old issued by the National Health Commission of the People's Republic of China (WS/T 423-2022).
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Head circumference
The change of head circumference to the baseline in children aged 0-3 years old, and the proportion of head circumference in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old issued by the National Health Commission of the People's Republic of China (WS/T 423-2022).
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Dose adjustment changes
The changes of dose adjustment in glycerol phenylbutyrate throughout the study
Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)
Mean Neonatal Behavioral Neurological Assessment Scores: Behavioral ability, passive muscle tone, active muscle tone, primitive reflexes, and general assessment
The neonatal behavioral neurological assessment (NBNA) scale was used for newborn participants who were at least 2 months of age, consisting of 20 items, with a maximum score of 40 points. The total scores of the NBNA are derived from the cumulative sum of the scores obtained in behavioral ability (6 items), passive muscle tone (4 items), active muscle tone (4 items), primitive reflexes (3 items), and general assessment (3 items), which are collected according to the scales have been actually completed by the subjects in the clinical practice. The total scores greater than 37 is considered normal, while a score less than or equal to 37 is considered abnormal.
Month 6, every year thereafter (1-5 years)
Mean Bayley Scale of Infant Development Scores: mental scale, motor scale
The Bayley Scale of Infant Development was used for infant participants whose ages range from 2 months to 30 months, consisting of 244 behavioral items, including 163 items on the mental scale and 81 items on the motor scale. The scores of each infant on the mental and motor scales are converted into standard scores with a mean of 100 and a standard deviation of 16 according to age groups, thereby calculating the Mental Development Index (MDI) and the Psychomotor Development Index (PDI). A total score of MDI and PDI, which are collected according to the scales have been actually completed by the subjects in the clinical practice, are less than 70 indicates developmental delay, 70-79 indicates a borderline state, 80-89 indicates low average, 90-109 indicates average, 110-119 indicates high average, 120-129 indicates superior, and a score of 130 or above indicates very superior.
Month 6, every year thereafter (1-5 years)
Mean Gesell Developmental Diagnosis Scale Scores
The assessment for Gesell Developmental Diagnosis Scale Scores was used for participants whose ages range from 30 months to 6 years, including five areas: gross motor skills, fine motor skills, adaptive behavior, language, and personal-social behavior. The observed behavioral patterns are identified based on the standard of normal behavioral patterns and are expressed in terms of age. This age is then compared with the actual age to calculate the Developmental Quotient (DQ), which is DQ = Developmental Age / Actual Age × 100, and the values of DQ are collected according to the scales have been actually completed by the subjects in the clinical practice. A DQ of 85 or above is considered normal for the nervous system, a DQ between 75 and 85 (inclusive of 75 but exclusive of 85) indicates a borderline level of nervous system impairment, and a DQ below 75 indicates nervous system damage.
Month 6, every year thereafter (1-5 years)
Mean Wechsler Preschool and Primary Scale of Intelligence Scores: The Verbal Intelligence Quotient, the Performance Intelligence Quotient
The Chinese - Wechsler Preschool and Primary Scale of Intelligence (C - WYCSI) was used for children participants whose ages range from 4 to 6 years. The Verbal Intelligence Quotient (VIQ) test includes five subtests: Information, Picture Vocabulary, Arithmetic, Picture Comprehension, and Comprehension. The Performance Intelligence Quotient (PIQ) test includes five subtests: Animal Hatching, Picture Completion, Mazes, Geometric Shapes, and Block Design. The intelligence quotient (IQ) score obtained from the 10 subtests of VIQ and PIQ is the Full Intelligence Quotient (FIQ). The values for VIQ, PIQ and FIQ are collected according to the scales have been actually completed by the subjects in the clinical practice. FIQ is divided into five levels: ≥130 is superior, 116 - 129 is above average, 85 - 115 is average, 70 - 84 is below average, and \< 70 is intellectual disability.
Month 6, every year thereafter (1-5 years)
Mean Wechsler Intelligence Scale for Children Scores: The Verbal Intelligence Quotient, the Performance Intelligence Quotient
The Chinese-Wechsler intelligence scale of children (C-WISC)was used for participants whose ages range from 7 to 18 years. This scale consists of 11 subtests. The Verbal Intelligence Quotient (VIQ) test includes Information, Comprehension, Similarities, Arithmetic, Digit Span, and Vocabulary. The Performance Intelligence Quotient (PIQ) test includes Picture Completion, Picture Arrangement, Block Design, Object Assembly, and Coding. First, the raw score is calculated based on the test results of the examinee. Then, the corresponding age-specific scale score coefficient is checked and converted into a scale score. The sum of the VIQ and PIQ scale scores is the full intelligence quotient (FIQ) score, which are collected according to the scales have been actually completed by the subjects in the clinical practice. A FIQ of ≥120 is classified as high intelligence, 90-119 is classified as normal intelligence, and a score \< 90 is classified as low intelligence.
Month 6, every year thereafter (1-5 years)
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Kind, Erwachsene
Mindestalter
0 Years
Zugelassene Geschlechter
Alle
  1. Male or female aged 0-18 years;
  2. Subject and/or subject's legally authorized representative willing to follow the therapeutic regimen, dietary management and visit plan of the study, and voluntarily signing informed consent form;
  3. Patients with the following subtypes of UCD: Carbamoyl phosphate synthetase I deficiency, Ornithine translocase deficiency, citrullinemia type I, argininosuccinic aciduria, argininemia, and hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome;
  4. Patients planned to use glycerol phenylbutyrate who have not used it in past 3 months (including at the time of 3 months);
  5. Men with fertility and women of childbearing potential (with menstruation) who are willing to take effective contraceptive measures during the period from the date of signing the informed consent to 1 months after the last dose of the study drug, such as abstinence, condoms, intra-uterine contraceptive devices, and double barrier methods (such as condoms + contraceptive diaphragms). Pregnancy test results must be negative for women of childbearing age within ≤ 7 days before the initial administration of study drug.

  1. Hypersensitivity to any of the active ingredient, including phenylbutyrate (PBA), phenylacetate acid (PAA) and phenylacetyl glutamine (PAGN), or excipients;
  2. Use of any drug known to significantly affect renal clearance (such as probenecid) or increase protein catabolism (such as corticosteroids) or other drugs known to increase blood ammonia levels (such as valproate) within 24 h before the first administration;
  3. Use of other nitrogen-scavenging agent at the same time after enrollment, such as sodium phenylbutyrate and sodium benzoate;
  4. Pregnant or breastfeeding females.
  5. Other reasons, in the opinion of the investigator, that may affect the patient's compliance and safety in participating in the study.
Tongji Hospital logoTongji Hospital
Verantwortliche Partei
Xiaoping Luo, Hauptprüfer, Professor, Tongji Hospital
Zentrale Studienkontakte
Kontakt: Xiaoping Luo, M.D., 027-83662640, [email protected]
5 Studienstandorte in 1 Ländern

Beijing Municipality

Peking University First Hospital, Beijing, Beijing Municipality, 100034, China
Yang, M.D., Kontakt, 010-83572211, [email protected]
Offene Rekrutierung

Guangdong

Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, 510000, China
Liu, M.D., Kontakt, 020-81886332, [email protected]
Offene Rekrutierung

Hubei

Tongji Hosipital, Wuhan, Hubei, 430030, China
Luo, M.D., Kontakt, 027-83662640, [email protected]
Offene Rekrutierung

Shanghai Municipality

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, 200092, China
Qiu, M.D., Kontakt, 021-2507 8999, [email protected]
Offene Rekrutierung

Zhejiang

Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Dong, M.D., Kontakt, 0571-87061007, [email protected]
Noch nicht rekrutierend